Review Article
Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept
Table 2
Trials of anti EGFR monoclonal antibodies.
| | Phase | Number of patients | Anatomic site | Histology | Treatment regimen | Outcomes | Comments |
| Gold et al. [21] | II | 55 | Esophagus | 55/55 adenocarcinoma | Cetuximab 400 mg/ , then 250 mg/ IV weekly | mOS 4 months mPFS 1.8 months | 2nd line treatment | | | | | | | | | Ku et al. [22] | II | 8 | Esophagus/GEJ | 7/8 adenocarcinoma (87%) 1/8 squamous cell (13%) | CPT 11 65 mg/ + Cisplatin 30 mg/ weekly 2/3 weeks Cetuximab 400 mg/ 1, then 250 mg/ IV weekly | mTTP 4.4 months 1 PR, 2 SD | All patients received prior CPT 11/cisplatin Accrual ongoing | | | | | | | | | Pinto et al. [23] | II | 38 | 34/38 Gastric 4/38 GEJ | 38/38 adenocarcinoma | CPT 11 180 mg/m2 IV D1 5-FU 400 mg/ IV bolus D1, 5-FU 600 mg/ CIVI D1-2, Leucovorin 100 mg/ IV D1 every 2 weeks 24 weeks (FOLFIRI) Cetuximab 400 mg/ 1, then 250 mg/ IV weekly | mTTP 8 months median expected survival 16 months 4/34 CR (12%), 11/34 PR (32%), 16/34 SD (47%) | Untreated advanced/ metastatic disease | | | | | | | | | Han et al. [24] | II | 38 | 38/38 gastric | 38/38 adenocarcinoma | Oxaliplatin 100 mg/m2 IV D1 Leucovorin 100 mg/ IV D1, 5-FU 1200 mg//d CIVI 46 hours (mFOLFOX6) Cetuximab 400 mg/ 1, then 250 mg/IV weekly | mTTP 5.5 months mOS 9.9 months 19/38 PR (50%), 16/38 SD (42%) | EGF and TGF-alpha levels inversely correlated with response |
|
|
mOS: median overall survival; mPFS: median progression free survival; PR: partial response; SD: stable disease; GEJ: gastroesophageal junction; TTF: time to failure; TTP: time to progression; CPT 11: irinotecan; EGF: epidermal growth factor; TGF-alpha: transforming growth factor-alpha.
|